This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Drug Enforcement Administration (DEA) will move to reclassify cannabis — a historic shift that could have wide ripple effects across the country. Understanding current drug scheduling for cannabis The DEA classifies drugs, substances, and certain chemicals used to make drugs into five distinct categories or “schedules.”
Members of the House Energy and Commerce Subcommittee on Health today held a legislative hearing, “ Cannabis Policies for the New Decade ,” during which they considered multiple legislative bills aimed at amending federal cannabis laws. He continued: “The fact of the matter is that legalization and regulation work.
Research from New Frontier Data estimates that around 3 million people grow their own cannabis at home in the United States. The research conducted by New Frontier Data went on to show that 65% of those who grow cannabis at home were in a relationship or married, and 46% had children under the age of 18. Will you be one of them?
A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. Lastly, the guide lays out the complex DEA registration process researchers much navigate to gain access to plants like psilocybin.
million cultivated marijuana plants and made more than 6,600 marijuana-related arrests in 2021, according to annual data compiled by the US Drug Enforcement Administration. . Federal law enforcement agents and their partners seized over 5.5 million cultivated cannabis plants last year – a 20 percent increase over 2020’s totals.
So while a cannabis business can join their local chamber of commerce, a patient in hospice can be denied access to medical cannabis. There is a shift happening in this country, away from liberal policies, including drug policy reforms. Restricted access and fear-mongering is the vibe, not freeing the plant and healing people.
Researchers have taken a big step in understanding the connection between using psychedelics and feeling connected to nature in a study published in the journal Drug Science, Policy, and Law on Oct. The subjective nature of self-reported data can plague research. Always consult a physician before attempting alternative therapies.
. – Today, ahead of the 50th anniversary—on June 17—of when President Richard Nixon declared the “war on drugs,” Representatives Bonnie Watson Coleman (D-NJ) and Cori Bush (D-MO) unveiled the Drug Policy Reform Act (DPRA), alongside the Drug Policy Alliance, which has been a strategic partner on the development of the legislation.
.” 1 Unless otherwise indicated, market share data disclosed in this press release is calculated using the Company’s internal proprietary market share tool that utilizes point of sales data supplied by a third-party data provider, government agencies and our own retail store operations across the country.
Later that year, Doblin sued the DEA for the first time. MAPS hired Sylvia Thyssen as our first employee , celebrated the 50th anniversary of LSD , outlined perspectives on drug policy , and worked toward facilitating a pilot study for medical marijuana. Lyle Craker, Ph.D.,
1 Unless otherwise indicated, market share data disclosed in this press release is calculated using the Company’s internal proprietary market share tool that utilizes point of sales data supplied by a third-party data provider, government agencies and our own retail store operations across the country. Webcast Information.
Like others, Dr. Beasley is forced by default to expand her knowledge base through scientific facts that warrant closer inspection and through accessible existing research, with few current cannabis case studies. Cannabis is not a “gateway” drug, according to the ASA and the DEA’s own statements cited in the August 2016 U.S.
Which Cannabis Strains Are Highest in CBD, According to Lab Data? Bummer: Patients Are Still Struggling for Cannabis Access. There’s nothing to justify the sky-high price (about $90 per day) beyond the cost of research and development to win FDA approval. RELATED STORY. RELATED STORY.
All that is about to change, thanks to a change at the DEA , which cultivators and industry experts say will be monumental for cannabis research, medical marijuana patients, and potentially the broader legal status of the plant itself. “We Unfortunately, this change in policy has been promised for years and never actually materialized.”.
MORE DETAILS: On June 16, 2014, Florida became the 22nd state to legalize (at least partial) access to medical marijuana when Governor Rick Scott signed the Compassionate Medical Cannabis Act of 2014. To learn more about telehealth appointments and CannaMD ‘s COVID-19 safety measures, see: Coronavirus Policies.
Drug Enforcement Agency (DEA) to the Alcohol and Tobacco Tax and Trade Bureau (TTB), the Bureau of Alcohol Tobacco Firearms and Explosives (ATF). It would transfer primary agency jurisdiction over cannabis from the DEA to the FDA, TTB, and ATF. If implemented, regulatory responsibility of cannabis would be transferred from the U.S.
8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. DEA and the Controlled Substances Act. In addition to the arduous FDA approval process, potential psychedelic therapies would also require complying with requirements from the Drug Enforcement Administration (DEA).
Should President Biden wish to acknowledge the political, economic, and moral realities surrounding cannabis policy, and fulfill the promises he made on the campaign trail, this report lays out a clear roadmap for how to do so.”. We’re beyond that.”. The FDA Director role continues to be unfilled. That’s all it is.
The investigation covered a lot of important ground, but the main results concern the levels of delta-9 THC in each product, the inaccuracy of the labeling, how easily minors can get access to products and whether companies test for impurities. Every lab uses a different method so the data is not going to be consistent.”.
In recent months, a synthetic compound derived from hemp called THC-O acetate—often referred to simply as THC-O (pronounced “THC oh”)—has quickly gained popularity among Americans who don’t have access to legal cannabis. . THC-O products are increasingly popular in states where consumers don’t have access to legal cannabis.
This leaves room for further growth, which may occur from the recent legalization of smokable flower and continued wide access to dispensaries.” Namely that Florida is the second-fastest-growing market in terms of patients joining the registry, with registered patients making up 1.6% of the state’s total population.
As policies become more data-driven and progressive, cultivation and production technologies have continued to improve drastically over the past several years. The DEA still classifies cannabis as a Schedule I controlled substance, a designation reserved for drugs with no medical value and a high potential for abuse.
Despite overwhelming evidence that psilocybin is misclassified, this barrier restricts research, stifles competition and innovation, and inhibits access. But only if it is made affordable and accessible. Psilocybin’s federal status as a Schedule I controlled substance is to blame. For two decades, U.S. The first is legislative.
Because cannabis is still illegal under federal law, the DEA and other federal law enforcement would be able to use federal funds to shut down medical marijuana programs. The data speaks for itself. No patient should have to worry about losing access to cannabis treatment options. Thanks for being in the fight with us, NORML.
Both paths are complex processes in which scientific, medical, policy and political forces have influence. There are other avenues Congress can take besides rescheduling marijuana to ameliorate the seeming breakdown in federalism brought about by federal marijuana policy. It was not a policy priority of the Obama administration.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content